男性低促性腺激素性性腺功能减退症长期生殖激素治疗后骨密度正常化的证据不充分
该系统综述与荟萃分析纳入33项研究(其中24项含HH男性数据,n=625),发现HH男性腰椎和股骨颈骨密度低,激素治疗后可改善。5项研究的荟萃分析显示HH男性腰椎骨密度低于健康对照(SMD -5.98;95% CI -11.5至-0.47)。先天性HH患者即使长期治疗骨密度可能仍持续偏低,提示骨密度完全正常化不充分。
要点
- HH男性腰椎和股骨颈骨密度降低,生殖激素治疗可改善骨密度。
- 荟萃分析显示HH男性腰椎骨密度显著低于健康对照(SMD -5.98)。
- 先天性HH患者长期治疗后骨密度可能仍持续偏低,完全正常化不充分。
核心结论
- HH男性骨密度低,生殖激素治疗可改善,但长期治疗后骨密度不完全正常化可能常见,尤其先天性HH患者。
研究设计与样本
- 系统综述与荟萃分析,检索OVID Medline、Embase、CINAHL、SCOPUS、Web of Science和Cochrane Library。
- 33项符合条件的研究,其中24项含HH男性特异性数据(n=625)。
- 采用描述性统计总结结果,荟萃分析比较HH男性与健康对照的骨密度,荟萃回归评估治疗时长与骨密度Z值的关系。
主要发现
- HH男性腰椎和股骨颈骨密度低,激素治疗后可改善。
- 5项研究的荟萃分析显示HH男性腰椎骨密度低于健康对照(SMD -5.98;95% CI -11.5至-0.47)。
- 先天性HH患者即使长期激素治疗,骨密度可能仍持续偏低。
- HH患者骨密度较高与治疗开始年龄较轻、部分性HH、血清睾酮和雌二醇浓度较高相关。
- 少数系统研究骨折结局的研究中骨折患病率高,其他研究中骨折少有报告。
临床怎么用
- 对HH男性应评估骨密度,并在生殖激素治疗中监测骨密度变化。
- 先天性HH患者即使长期治疗,仍需关注骨密度不完全正常化的可能。
- 治疗开始年龄较轻、部分性HH及较高的睾酮和雌二醇水平与较高骨密度相关。
局限性
- 纳入研究多为小型观察性研究,证据不完整。
- 骨折结局仅在少数研究中系统评估,其他研究少有报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The prevalence and severity of low bone mineral density (BMD) in hypogonadotropic hypogonadism (HH), as well as the ability of reproductive hormone treatment to normalize BMD have not been investigated in large multicenter studies. OBJECTIVE: We performed a systemic review and meta-analysis of several small, observational studies to investigate the effect of reproductive hormone treatment on BMD in men with HH compared with control groups where available. METHODS: We searched OVID Medline, Embase, CINAHL, SCOPUS, Web of Science, and Cochrane Library for studies reporting BMD or fractures in men with HH (congenital [CHH] or acquired). Study selection and data extraction were performed using COVIDENCE and a prespecified tool. Results were summarized using descriptive statistics. Meta-analysis compared BMD in men with HH vs healthy controls. Meta-regression assessed relationships between treatment duration and BMD Z-scores against normative population data. RESULTS: Of the 33 eligible studies, 24 included data specific to men with HH (n = 625). Men with HH had low lumbar spine (LS) and femoral neck BMD, improving with hormonal treatment. Meta-analysis of 5 studies found lower LS BMD in men with HH vs healthy controls (SMD -5.98; 95% CI; -11.5 to -0.47). Men with CHH may have persistently low BMD despite prolonged hormonal treatment. Higher BMD in HH was associated with younger age at treatment initiation, partial HH, and higher serum testosterone and estradiol concentrations. Fracture prevalence was high in the few studies systematically studying fractures as an outcome; in other studies, fractures were seldom reported. CONCLUSION: Men with HH have low BMD that improves with reproductive hormone treatment. However, current evidence suggests that incomplete BMD normalization may be common despite long-term reproductive hormone treatment in men with HH, particularly those with CHH.
引用
- de Silva NL, Hyams E, Grant B, et al. Incomplete Evidence of Bone Density Normalization Following Long-Term Reproductive Hormone Treatment in Men With Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab. 2025. PMID: 41032457. doi:10.1210/clinem/dgaf488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。